Antegrade Autologous Blood Reinfusion After CPB

NCT07420582 | Recruiting

• 1 other identifier: KSH_ZYT_1
• Study Type: observational
• Target: 130
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.

Conditions

Coronary Artery Disease

Outcome Measures

Primary Outcomes (1)

• Postoperative Blood Transfusion Requirement

  Incidence of allogeneic blood transfusion within the first 24 hours after surgery.

  From the end of surgery to 24 hours postoperatively

Secondary Outcomes (2)

• Postoperative Drainage Volume

  From the end of surgery to 24 hours postoperatively

• Number of Transfused Blood Units

  From the end of surgery to 24 hours postoperatively

Study Arms (2)

Antegrade Pump Blood Reinfusion (Chase Technique)

Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.

Procedure: Antegrade Pump Blood Reinfusion

No Pump Blood Reinfusion

Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is not performed at the end of bypass, and standard clinical management is applied.

Other: No Anterograde Pump Blood Reinfusion

Interventions

Antegrade Pump Blood Reinfusion PROCEDURE

Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.

Antegrade Pump Blood Reinfusion (Chase Technique)

No Anterograde Pump Blood Reinfusion OTHER

Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom anterograde pump blood reinfusion is not performed at the end of bypass. Standard institutional clinical management is applied.

No Pump Blood Reinfusion

Eligibility Criteria

• Age: 18 Years - 80 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population includes adult patients (18-80 years) scheduled for elective, primary isolated coronary artery bypass grafting (CABG) using cardiopulmonary bypass at Kocaeli City Hospital.

You may qualify if:

• Age 18 to 80 years
• Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).

You may not qualify if:

• Emergency or Redo cardiac surgery
• Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
• Planned or intraoperative conversion to off-pump coronary artery bypass grafting
• Preoperative hematocrit \<30% or known inherited/acquired bleeding disorders.
• Preoperative left ventricular ejection fraction \<30%.
• Thrombocytopenia (e.g., platelet count \<100×10³/µL) or abnormal coagulation tests.
• Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
• Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
• Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
• Severe renal dysfunction (eGFR \<30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction (Child-Pugh B-C or coagulopathy).
• Active infection or systemic inflammatory/autoimmune disease.
• Active malignancy requiring ongoing treatment
• Refusal or inability to provide written informed consent.

Sponsors & Collaborators

• Kocaeli City Hospital: lead

Study Sites (1)

Kocaeli City Hospital

Kocaeli, Izmit, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Zeynep Yasemin Tavsanoglu, MD

  Kocaeli City Hospital, Department of Anesthesiology and Reanimation

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yılmaz

CONTACT

+902622252700; kocaelish@saglik.gov.tr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Medical Doctor

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: February 19, 2026
• Study Start: February 23, 2026
• Primary Completion: June 1, 2026
• Study Completion: June 15, 2026
• Last Updated: February 24, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)